Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Takafumi Yamamoto; Takanori Ito; Tetsunari Hase; Masatoshi Ishigami; Kazuyuki Mizuno; Kenta Yamamoto; Norihiro Imai; Yoji Ishizu; Takashi Honda; Hirofumi Shibata; Takahiro Hatta; Naoyuki Yogo; Satoshi Yasuda; Hidenori Toyoda; Takashi Abe; Hiroki Kawashima; Naozumi Hashimoto; Mitsuhiro Fujishiro

doi:10.1080/07357907.2021.1994586

Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Takafumi Yamamoto, Takanori Ito, Tetsunari Hase, Masatoshi Ishigami, Kazuyuki Mizuno, Kenta Yamamoto, Norihiro Imai, Yoji Ishizu, Takashi Honda, Hirofumi Shibata, Takahiro Hatta, Naoyuki Yogo, Satoshi Yasuda, Hidenori Toyoda, Takashi Abe, Hiroki Kawashima, Naozumi Hashimoto, Mitsuhiro Fujishiro

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

It remains unclear whether severe liver immune-related adverse events (liver-irAEs) can affect the prognosis in nonsmall cell lung carcinoma (NSCLC) patients. Of the 365 NSCLC patients treated with immune checkpoint inhibitors (ICIs), 19 suffered from severe liver-irAEs (grade ≥3). The median time-to-onset of liver-irAEs was 53 days postinjection of the first ICI. The progression-free survival and overall survival of the liver-irAEs group (median 69 and 262 days, respectively) were significantly worse than the nonliver-irAEs group (128 and 722 days; P = 0.010 and P = 0.007; respectively). In conclusion, liver-irAEs were associated with poor prognosis in NSCLC patients.

Original language	English
Pages (from-to)	189-198
Number of pages	10
Journal	Cancer Investigation
Volume	40
Issue number	2
DOIs	https://doi.org/10.1080/07357907.2021.1994586
Publication status	Published - 2022
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/07357907.2021.1994586

Cite this

Yamamoto, T., Ito, T., Hase, T., Ishigami, M., Mizuno, K., Yamamoto, K., Imai, N., Ishizu, Y., Honda, T., Shibata, H., Hatta, T., Yogo, N., Yasuda, S., Toyoda, H., Abe, T., Kawashima, H., Hashimoto, N., & Fujishiro, M. (2022). Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Cancer Investigation, 40(2), 189-198. https://doi.org/10.1080/07357907.2021.1994586

@article{e29600268e0d4377beca98baaf57aeb0,

title = "Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors",

abstract = "It remains unclear whether severe liver immune-related adverse events (liver-irAEs) can affect the prognosis in nonsmall cell lung carcinoma (NSCLC) patients. Of the 365 NSCLC patients treated with immune checkpoint inhibitors (ICIs), 19 suffered from severe liver-irAEs (grade ≥3). The median time-to-onset of liver-irAEs was 53 days postinjection of the first ICI. The progression-free survival and overall survival of the liver-irAEs group (median 69 and 262 days, respectively) were significantly worse than the nonliver-irAEs group (128 and 722 days; P = 0.010 and P = 0.007; respectively). In conclusion, liver-irAEs were associated with poor prognosis in NSCLC patients.",

author = "Takafumi Yamamoto and Takanori Ito and Tetsunari Hase and Masatoshi Ishigami and Kazuyuki Mizuno and Kenta Yamamoto and Norihiro Imai and Yoji Ishizu and Takashi Honda and Hirofumi Shibata and Takahiro Hatta and Naoyuki Yogo and Satoshi Yasuda and Hidenori Toyoda and Takashi Abe and Hiroki Kawashima and Naozumi Hashimoto and Mitsuhiro Fujishiro",

note = "Publisher Copyright: {\textcopyright} 2021 Taylor & Francis Group, LLC.",

year = "2022",

doi = "10.1080/07357907.2021.1994586",

language = "English",

volume = "40",

pages = "189--198",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "2",

}

Yamamoto, T, Ito, T, Hase, T, Ishigami, M, Mizuno, K, Yamamoto, K, Imai, N, Ishizu, Y, Honda, T, Shibata, H, Hatta, T, Yogo, N, Yasuda, S, Toyoda, H, Abe, T, Kawashima, H, Hashimoto, N & Fujishiro, M 2022, 'Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors', Cancer Investigation, vol. 40, no. 2, pp. 189-198. https://doi.org/10.1080/07357907.2021.1994586

TY - JOUR

T1 - Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

AU - Yamamoto, Takafumi

AU - Ito, Takanori

AU - Hase, Tetsunari

AU - Ishigami, Masatoshi

AU - Mizuno, Kazuyuki

AU - Yamamoto, Kenta

AU - Imai, Norihiro

AU - Ishizu, Yoji

AU - Honda, Takashi

AU - Shibata, Hirofumi

AU - Hatta, Takahiro

AU - Yogo, Naoyuki

AU - Yasuda, Satoshi

AU - Toyoda, Hidenori

AU - Abe, Takashi

AU - Kawashima, Hiroki

AU - Hashimoto, Naozumi

AU - Fujishiro, Mitsuhiro

PY - 2022

Y1 - 2022

N2 - It remains unclear whether severe liver immune-related adverse events (liver-irAEs) can affect the prognosis in nonsmall cell lung carcinoma (NSCLC) patients. Of the 365 NSCLC patients treated with immune checkpoint inhibitors (ICIs), 19 suffered from severe liver-irAEs (grade ≥3). The median time-to-onset of liver-irAEs was 53 days postinjection of the first ICI. The progression-free survival and overall survival of the liver-irAEs group (median 69 and 262 days, respectively) were significantly worse than the nonliver-irAEs group (128 and 722 days; P = 0.010 and P = 0.007; respectively). In conclusion, liver-irAEs were associated with poor prognosis in NSCLC patients.

AB - It remains unclear whether severe liver immune-related adverse events (liver-irAEs) can affect the prognosis in nonsmall cell lung carcinoma (NSCLC) patients. Of the 365 NSCLC patients treated with immune checkpoint inhibitors (ICIs), 19 suffered from severe liver-irAEs (grade ≥3). The median time-to-onset of liver-irAEs was 53 days postinjection of the first ICI. The progression-free survival and overall survival of the liver-irAEs group (median 69 and 262 days, respectively) were significantly worse than the nonliver-irAEs group (128 and 722 days; P = 0.010 and P = 0.007; respectively). In conclusion, liver-irAEs were associated with poor prognosis in NSCLC patients.

UR - http://www.scopus.com/inward/record.url?scp=85120041816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120041816&partnerID=8YFLogxK

U2 - 10.1080/07357907.2021.1994586

DO - 10.1080/07357907.2021.1994586

M3 - Article

C2 - 34658277

AN - SCOPUS:85120041816

SN - 0735-7907

VL - 40

SP - 189

EP - 198

JO - Cancer Investigation

JF - Cancer Investigation

IS - 2

ER -

Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this